🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Analysis: often is complex, depending also on Bayesian /frequentist framework. Important for readers to know fundamental principles met: prespecified, published SAP, blinded, IDMC - the perennials! #NephTrials

Tbh: would be great if SOC = receiving all proven treatments and enrolled in a trial testing new therapies. In the ideal world, that's the SOC period. #LearningHealthSystems. #NephTrials

Yes! Great work from Berry Consultants Liz Lorenzi. #NephTrials

That can be a challenge. The concept is - will receive one of a number of interventions or placebo. If not getting better after 4 weeks, will get an active treatment (but you won't know which one). #NephTrials

Thank-you! Including first author Brendan. Worth reading the original article led by Jule Pinter, MD shorturl.at/qxDK6. Challenging - observational evidence is confounded & can be difficult to interpret. An eg of where randomisation is needed for true quality assessment

Excess mortality in HD patients is associated with abnormal fluid status and plasma sodium concentrations. This study stresses the need for randomized evidence to reliably define optimal standard dialysate sodium prescribing practices bit.ly/JASN0262 David C Wheeler

An exciting time for kidney disease with lots of new therapies on the horizon. #KidneyHealthForAll is a timely reminder that we need to ensure equitable access as these emerge Int Society of Nephrology; Kidney Health Kidney Health Initiative

Always fun and informative to chat with Rajiv!

Had a fantastic time at the InaSN meeting discussing the latest #KDIGO_CKD_Guidelines. With new therapies, access & implementation now a key focus. Nephrology Journal Club will also be discussing - online May 21/22 Thanks to Dr Pringgo & team for a warm welcome and to #ISN for support

Did you know the NHMRC NHMRC CTC is now conducting 20 adaptive platform trials. Congratulations to all academic and operations staff involved! Sydney Health University of Sydney ACTA: Australian Clinical Trials Alliance ACTA Australian Clinical Trials Alliance NSW Agency for Clinical Innovation NSW Health

Angiopoietin 2 regulates endothelial function partially mediated by VEGF-A. This study found higher angiopoietin 2 levels were associated with cardiorenal risk among individuals with DKD independent of VEGF-A bit.ly/CJASN0389 Meg Jardine @[email protected] @RezaMohebiMD Metabolic Medicine

📢 Prepare for the new treatment landscape 📢 #SGLT2 inhibitors are foundational for prevention & treatment of complications in many adults. Our definitive plenary review summarises the state of the art for SGLT2is & addresses common questions such as: How do they actually

The only way to slow down #kidneydisease is to catch it early, before symptoms appear.​ Take the 2min risk test online now: bit.ly/4ajU24a #KidneyActionWeek #deadlyserious

📢 Call for Nominations Nominate the next ISN: 👤President-Elect & 👥Regional Board Deputy Chairs/Council members for all 10 ISN regions Deadline: 12 July at 5:00 pm CEST Act now: bit.ly/4b1hBzf

Great summary of clinical effects, mechanisms of action and health economic evaluations led by Daniel O'Hara

Truly inspirational. Wonderful to hear some of the insights on trial that saved a million lives in a year. A tribute to the many different organisations involved. Can we harness this same collaborative approach to addressing the epidemic of chronic disease?

Congratulations to Canadian Nephrology Trials Network Committee member Dr. David Collister David Collister on his successful Accelerating Clinical Trials Canada RFA 5 application for "Better Evidence And Translation for Calciphylaxis (BEAT-Calci) global platform trial" with Dr. Meg Jardine. Meg Jardine @[email protected] act-aec.ca/rfa-5-announce…

In this article, Meg Jardine @[email protected] and RathikaKrish discusses the benefits and challenges of adaptive designs for clinical trials for kidney diseases like calciphylaxis. bit.ly/JASN0497

Counting down the Top Ten #NephMadness region posts from 2020-2024: 9️⃣ SGLT2i Region (2020) bit.ly/42ZZRDZ Expert: Meg Jardine @[email protected] Writer: Harish Seethapathy Exec: Joel M. Topf, MD FACP Teams: - TG Feedback vs Non-TG Feedback - SGLT2i in Transplant vs SGLT2i Without Diabetes